仟源医药（300254.SZ）8月6日在投资者互动平台表示，公司依巴斯汀片主要治疗过敏性鼻炎、慢性特 发性荨麻疹以及其他皮肤过敏疾病；对于过敏性鼻炎，依巴斯汀片可有效缓解鼻痒、打喷嚏、流鼻涕、 鼻塞等症状。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司子公司江苏嘉逸医药最近获批的依巴斯汀 化学原料药是治疗过敏性鼻炎和荨麻疹的吗？过敏性鼻炎一直是鼻炎里的顽症，贵公司的药品对治疗效 果如何？ ...

Core Viewpoint - QianYuan Pharmaceutical (300254) announced that its subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., received the approval notice for the listing application of Ebastine raw materials from the National Medical Products Administration [1] Group 1: Product Approval - Ebastine is indicated for the symptomatic treatment of allergic rhinitis with or without allergic conjunctivitis and chronic idiopathic urticaria [1] - The original manufacturer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A. [1] Group 2: Market Impact - The Ebastine tablets produced by the subsidiary Hangzhou QianYuan BaoLing Pharmaceutical Co., Ltd. have passed the consistency evaluation [1] - Ebastine has been included in the Class B National Medical Insurance Directory, which may enhance its market accessibility [1] Group 3: Cost and Competitiveness - The approval of Ebastine raw materials for market entry is expected to further reduce the production costs of the formulation products [1] - This reduction in costs is anticipated to enhance the market competitiveness of the products [1]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is actively pursuing innovation-driven development strategies, focusing on R&D, market expansion, and strategic acquisitions to enhance its position in the pharmaceutical industry [1][2][3][4][5][6][7][8] Group 1: Innovation and R&D - The company is increasing its R&D investment, with a projected total of approximately 277 million yuan for 2024, representing a year-on-year growth of about 96% [6] - Lianhuan Pharmaceutical has established multiple R&D platforms and is focusing on innovative drug development in areas such as cardiovascular, urology, and oncology, with six innovative drugs in the pipeline [4][5] - The company has received multiple drug registration certificates in 2023, including for products like Olmesartan and Furosemide, enhancing its product portfolio [5] Group 2: Strategic Acquisitions - Lianhuan Pharmaceutical's subsidiary, Yangzhou Lianhuan Investment Co., Ltd., plans to acquire a 51% stake in Sichuan Longyi Pharmaceutical for 70.38 million yuan, aiming to strengthen its market presence in Southwest China [2][3] - Earlier in January, the company acquired a 54% stake in Changle Pharmaceutical for 183.26 million yuan, further expanding its portfolio and market reach [3] - The company is committed to continuous investment and acquisition strategies to integrate quality resources and enhance its industry position [3] Group 3: Production Capacity Expansion - Lianhuan Pharmaceutical is increasing the registered capital of its subsidiary, Lianhuan (Anqing) Co., Ltd., from 50 million yuan to 130 million yuan to enhance its production capabilities [7][8] - The Anqing facility is crucial for the company's manufacturing layout and is expected to produce various formulations, including oral solutions and topical preparations [8] - The company has received a drug production license for the Anqing facility, which will contribute to its ability to supply high-quality products [7][8] Group 4: Financial Performance and Shareholder Returns - The company has maintained a consistent dividend payout ratio of 30% over the years, with total dividends of approximately 43.07 million yuan, 42.82 million yuan, and 25.41 million yuan from 2022 to 2024 [8] - Analysts predict that through its strategic initiatives, the company's overall revenue could exceed 4 billion yuan in 2023 [3]

Core Viewpoint - The company, Qianyuan Pharmaceutical, operates in the pharmaceutical industry, focusing on the research, production, and sales of pharmaceuticals and health products, as well as medical services [4]. Company Overview - Qianyuan Pharmaceutical is engaged in the development, production, and sales of various pharmaceutical products, including antibiotics, anti-allergy drugs, and medications for respiratory and urinary systems [4]. - The company also offers health products and medical services, including genetic preservation and environmental testing [4]. Business Model - The procurement process is centralized, with a focus on quality control and cost management [6]. - The production model is based on "sales-driven production," ensuring that production aligns with market demand [6]. - The sales strategy combines distribution through qualified dealers and academic promotion services [7]. Financial Data - The company has not restated or adjusted previous financial data [8]. - The company received a standard unqualified audit opinion from its accounting firm, indicating no significant issues with its financial reporting [3]. Important Events - The company returned 50 million yuan of temporarily idle raised funds to its dedicated account [10]. - The board approved several resolutions regarding stock issuance and management changes during the reporting period [11][12]. - The company received a special fund of 4 million yuan for the consistency evaluation of a generic drug [13].